Journal of acquired immune deficiency syndromes (1999) 2018 03 27() doi 10.1097/QAI.0000000000001691
to evaluate factors associated with increased serum cholesterol levels during Interferon-free (IFN-free) Hepatitis C virus (HCV) therapy.
Prospective longitudinal study METHODS:: HIV-infected patients who started and successfully completed IFN-free therapy for chronic HCV infection were included. Patients were treated using two different regimens, based on the clinician’s opinion: sofosbuvir and ledipasvir (SOF/LDV), or paritaprevir co-administered with ombitasvir and Dasabuvir (PrOD). Both total and LDL cholesterol were evaluated at baseline, week 1, week 2, week 4, week 8, EOT, SVR4, SVR12 and SVR24.
The study population therefore comprised 85 patients reaching SVR, 42 (49.4%) of whom were treated with SOF/LDV and 43 (50.6%) with PrOD. Patients using SOF/LDV was showed a higher increase on both total and LDL cholesterol during treatment period than those receiving PrOD. Analyzing the overall increase from baseline to weeks 1, 2, 4, 8 and EOT, choice of HCV regimen was associated with differential increases in total cholesterol during therapy. After end of treatment, no differences were found between SOF/LDV and PrOD with respect to total cholesterol.
Our study suggests that the differential timing of the restoration of cholesterol metabolism in HIV/HCV genotype 1 co-infected patients achieving SVR is not mediated by HCV clearance but depends on the drug combination employed.